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History o.f 
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Splanchnic Organ 
Transplantation 
Thomas E. Starzl, MD. PhD 
The history of whole organ engraftment has been told 
largely by those working with the kidney. I Many of these 
investigators and others in their laboratories began to fill 
the extrarenal vacuum in the late 1950s. The consequence 
was the rapid development of canine transplant models 
with which to study all of the intra-abdominal (Fig 1 - 1) 
and thoracic organs. The most fruitful of these efforts in-
volved the liver, which joined the kidney in the mid-1960s 
as the lead organ in the search for improved immunosup-
pression. The secondary gains from research in liver trans-
plantation included (1) new information about the meta-
bolic interrelations of the intra-abdominal viscera in 
disease and health; (2) a more profound understanding of 
the means by which all whole organ grafts are accepted; 
and (3) the addition of nontransplant as well as transplant 
procedures to the treatment armamentarium for gastroin-
testinal diseases. The way in which the liver was specifi-
cally involved in this complex chain of events is summa-
rized and annotated in Table 1- 1. 
EARLY ANIMAL MODELS 
The Liver 
Auxiliary Transplantation. The concept of liver trans-
plantation first appeared in the medical literature in 1955 
when C. Stuart Welch of Albany, New York, described the 
insertion of an extra (auxiliary) canine liver into the pelvis 
or right paravertebral gutter of nonimmunosuppressed re-
cipients.2 The allograft hepatic artery was revascularized 
from the aorta or iliac artery, and the portal flow was re-
stored by rerouting the high-volume systemic venous re-
turn of the host inferior vena cava into the graft portal vein 
(Fig 1 - 2). It was not discovered until a decade later that 
factors other than rejection contributed to the rapid de-
struction of the auxiliary transplant (see later section, 
Eck's Fistula and Hepatotrophic Physiology). 
Orthotopic Liver Transplantation. Liver replacement 
(orthotopic transplantation) (Fig 1-3) was first men-
tioned by Jack Cannon of the University of California, Los 
Angeles, who speculated that because the liver played an 
important role in rejection, it might refrain from contrib-
uting to its own repudiation. Although none of Cannon's 
dogs survived operation, his "Brief report" 3 was included 
with two articles by Welch and colleagues2. 4 on the subject 
of the liver in Woodruff's massive compendium of the en-
tire transplantation field to 1959. S By the time W oodruffs 
book was published in the following year, important inde-
pendent investigations of liver replacement (orthotopic 
transplantation) in dogs were completed; these had been 
started in the summer of 1958 at the Peter Bent Brigham 
Hospital in Boston6- 8 and at Northwestern University in 
Chicago.9, 10 The Boston effort, which was under the direc-
tion of Francis D. Moore, was a natural extension of an 
immunologically oriented institutional commitment to 
organ transplantation that was initially preoccupied with 
the kidney." 
In contrast, the Northwestern initiative stemmed from 
questions about the mutually regulatory interrelationship 
of insulin and the liverl2- 14 that ultimately led to a new 
field called hepatotrophic physiology. IS. 16 For these meta-
bolic investigations, a new technique of total hepatectomy 
was developed17 and followed, in July 1958, by the second 
step of inserting an allograft into the vacated hepatic fossa. 
From the outset, the premise was strongly supported that 
portal venous blood had superior liver-supporting quali-
ties compared with systemic venous blood.9 However, al-
most 20 years passed before the nature of the principal 
portal venous factors was clarified. 
3 
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Despite the absence of effective immunosuppression at 
that time, a solid basis for future work with orthotopic 
liver transplantation was laid throughout 1958 and 1959. 
At the April 1960 meeting of the American Surgical Asso-
ciation, Moore reported on 31 canine experiments with 7 
survivors of 4-12 days. In discussing his paper,18 I de-
scribed an experience9 with more than 80 dogs of whom 18 
had lived 4-201/2 days. Rejection was present after 5-6 
days in both series and was usually the principal explana-
tion for death. A few years later, Groth et al19 demon-
strated that drastic reductions in hepatic blood flow were 
an integral part of the rejection process and explained the 
infections to which the consequent ischemia made the 
liver prone.2O, 21 
Aside from elucidating the need to revascularize the he-
patic graft to supply splanchnic venous blood, these early 
investigations clarified the other requirements for success-
ful liver replacement. Preservation of the transplanted 
liver was accomplished with intraportal infusion of chilled 
electrolyte solutions in much the same way as is practiced 
clinically today.9 Improved infusates in the succeeding 
years22, 23 eventually replaced the lactated Ringer's and sa-
Figure 1-1 The complex of intra-
abdominal viscera that have been 
transplanted as a unit (center) or as 
separate comPonents: a, liver; b, pancreas; 
c, liver and intestine; d, intestine; and e, liver 
and pancreas. (From Starzl TE, Todo S, 
Tzakis A, Fung J. The transplantation of 
gastrOintestinal organs. Gastroenterology 
104:673-679, 1993.) 
line solutions that were used originally. Until 1987, how-
ever, the safe preservation time was only 5 -6 hours. Since 
then, the University of Wisconsin solution24 has permitted 
reliable and safe refrigeration of human livers for 18 - 24 
hours.2s, 26 
The final requirement for success in dogs was the use of 
plastic external venous bypasses that passively redirected 
blood from the occluded splanchnic and systemic venous 
beds to the superior vena cava during the anhepatic stage 
while recipient hepatectomy was performed and the new 
liver was installed.7,9 Such venous decompression was 
later shown to be expendable in dogs submitted to com-
mon bile duct ligation several weeks in advance of trans-
plantation. The safety factor was the development in the 
interim of decompressing venous collaterals.27 
Similarly, venous bypasses were shown to be nonessen-
tial in most clinical cases, if the operations were performed 
by highly experienced surgeons.28, 29 Nevertheless, the in-
troduction of pump-driven venovenous bypasses in the 
1980s, first with29,30 and then without3!-33 anticoagula-
tion, made the operation less stressful in humans and 
placed it well within the grasp of most competent general 
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TABLE 1 -1 History of liver transplantation 
Year 
1955 
1956 
1958-1960 
1960 
1963 
1963 
1964 
1963-1966 
1966 
1966 
1967 
1973-1976 
1976 
1979d 
1979 
1980 
1980 
1983 
1984 
1987 
1989 
1992 
1992 
Description 
First article in the literature on auxiliary liver transplantation (c. Stuart Welch) 
First article on orthotopic liver transplantation (Jack Cannon) 
Formal research programs on liver replacement at Harvard and Northwestern 
Multivisceral transplantation described, the forerunner of composite grafts 
Development of the azathioprine-prednisone cocktail (kidneys first, then livers) 
First human liver transplantation trial (University of Colorado) 
Confirmation of the portal venous blood hepatotrophic effect; defined the problem of auxiliary liver 
transplantation 
Improvements in preservation, in situ and ex vivo 
Introduction of antilymphocyte globulin (kidneys, then livers) 
First trial xenotransplantation (chimpanzee) 
First long survivals of human liver recipients (1967 - 1968), treated with azathioprine, prednisone, and 
antilymphocyte globulin 
Principal portal hepatotrophic substance identified as insulin 
Improved liver preservation (5-8 hr) permitting long-distance procurement 
Systematic use of arterial and venous grafts for vascular reconstruction 
Cyclosporine introduced for kidneys and liver 
Cyclosporine-steroid cocktail introduced for kidneys 
Cyclosporine-steroid cocktail for livers 
Pump-drlven venovenous bypass without anticoagulation 
Standardization of multiple organ procurement techniques 
University ofWlSCOnsin (UW) solution for improved preservation 
FKS06-steroid immunosuppression 
Discovery of chimerism as explanation of hepatic toierogenicity 
Baboon to human xenotransplantation 
Reference 
2 
3 
7, 9 
44,45,46 
99,100,104 
115 
65,66 
120, 129 
107 
160 
28 
15, 74 
22,23 
137 
III 
112 
29, 124 
31-33 
133,134 
24-26 
114 
153-156 
162 
and vascular surgeons, allowing the systematic training of 
a new generation of liver transplant surgeons (Fig 1-4). 
The way in which these refinements occurred has been re-
viewed elsewhere.34 
clinical successes with cadaver donors did not come until 
the late 1980s.42, 43 
Multivisceral Transplantation. At the time that isolated 
liver transplantation was being perfected in 1959, the 
more radical procedure of multiple organ engraftment 
(including the liver) was shown to be feasible.44 This trans-
plant was envisioned as a grape cluster with a double arte-
rial stem consisting of the celiac axis and superior mesen-
teric artery (Fig 1-6, left; and see Fig 1-1, center). In 
variations of the operation used clinically nearly 30 years 
later, the grapes, or individual organs, could be removed 
or retained according to the surgical objectives (Fig 1-6, 
right; and see Fig 1 - 1, periphery), but both sources of the 
arterial supply were preserved.4s The venous outflow was 
kept intact up to or beyond the liver. 
Multivisceral and Intestinal Transplantation 
Isolated Intestine. More than 90 years ago, Alexis Carrel 
(later working with c.c. Guthrie) performed canine intes-
tinal transplantations. 35 Little more was added until Rich-
ard Lillehei and his co-workers replaced almost the entire 
small intestine in unmodified dogs, after immersing it in 
iced saline for preservation.36 The blood vessels were anas-
tomosed to companion recipient structures in an anatom-
ically normal way (Fig 1-5). 
Unlike liver transplantation, which progressed steadily 
from the laboratory to the bedside, the clinical application 
of intestinal transplantation languished; this was so even 
after it was demonstrated in Toronto,37 London (On-
tariO),38 Pittsburgh,39 Kiel,40 and Paris41 that the gut could 
be successfully replaced and long-term survival achieved 
in large animals under immunosuppression. The first 
Two questions raised by the very earliest canine multi-
visceral experiments have remained clinically relevant 
since then. First, rejection of the organs making up the 
composite graft was less severe than expected on the basis 
of transplantation of the organs individually.46 Using dif-
ferent models, Calne and colleagues47 confirmed and 
Donor 
liver ... -Aorta 
- Hepatic a. 
_ Splenic a. 
- L. gastric a. 
iliac a. 
Figure 1 - 2 Auxiliary liver transplantation in dogs by a modification 
of Welch's original technique. Note that the reconstituted portal blood 
supply is from the distal inferior vena cava. I.V.C. = inferior vena cava. 
Marchioro TL, Rowlands DT Jr, et al. Immunosuppression after 
experimental and clinical homotransplantation of the liver. Ann Surg 
160:411-439,1964.) 
~g 
Bare area 
Com m 0 n b i I e -nrIKKKK-::"i--~itKKfel 
duct 
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Figure 1 - 3 Orthotopic liver transplantation (liver replacement). 
Biliary tract reconstruction is usually with choledochojejunostomy (to a 
Roux limb) or (inset) with a choledochocholedochostomy, which is 
stented with a T-tube. (From Starzl TE, Demetris AJ, Van Thiel DH. 
Medical progress: Uver transplantation, Part I. Reprinted with 
permission from The New England Journal of Medicine, 321,1014-
1022,1989.) 
o 
o 
Figure 1-4 Pump-dnven 
venovenous bypass, which allows 
decompression of the splanchnic 
and systemic venous beds without 
the need for heparinization. 
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Figure 1-5 Isolated small bowel transplantation. A. Donor operation; full-length vascular pedicle of 
the superior mesenteric artery (SMA) with a Carrel patch of aorta and the superior mesenteric vein 
(SMV). If both vessels are divided more distally. they can be lengthened on the back table with arterial 
and venous grafts (inset). PV = portal vein. B. Recipient operations. Anastomosis of the full-length 
SMA to the aorta and the angled end of the SMV to the portal vein. With an alternative method (lower 
inset). the SMV is anastomosed to the recipient SMV inferior to the pancreas. Another option (upper 
inset) is to direct the SMV dralnage into the inferior vena cava. (A and B from Todo S. Tzakis AG. 
Abu-Elmagd K. et aI. Intestinal transplantation in composite visceral grafts or alone. Ann Surg 
216:223-234. 1992.) 
Figure 1-6 The multivisceral 
transplantation originally 
developed in dogs (left) and a 
common variant (right) in which 
the central organs (pancreas and 
duodenum) are removed, leaving 
the liver and bowel. These two 
procedures have been perfonmed 
successfully in humans and 
provided the first examples of 
functioning bowel allografts. 
HA = hepatic artery. (From Starzl 
TE, Todo S. Tzakis A. Fung J. The 
transplantation of gastrointestinal 
organs. Gastroenterology 
104:673-679,1993.) 
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greatly extended this principle in 1969, when they de-
scribed the protection of kidney and skin grafts from the 
hepatic donor in pig liver recipients. These experiments 
identified the liver as the protective or tolerogenic organ. 
The hepatic protective effect has been confirmed by the 
Japanese surgeon Naoshi Kamada, whose experiments 
were performed in rats,48 and by many others. Most re-
cently, Valdivia et al49 demonstrated the cross-species 
protection of hamster heart and skin xenografts in rats by 
simultaneous or prior xenotransplantation of a hamster 
liver. 
The second fundamental issue raised by the transplan-
tation of a multi visceral graft or its component organs was 
the specter of graft-versus-host disease (GVHD), which 
was largely ascribed to the intestine rather than to the 
liver. 46 GVHD was well known in 1959 and 1960 from the 
research of Billingham and BrentSO and Trentin,51 but 
their observations had been almost exclusively based on 
bone marrow or splenocyte (not whole organ) transplanta-
tion. Histopathological evidence of GVHD was found in 
our canine multivisceral recipients,46 and GVHD was 
blamed for the quickly developing multiple organ failure 
in these animals. 
By 1965, it was realized that GVHD could also be 
caused by the liver when a humoral variety manifested by 
hemolysis was occurring in canine liver recipients52 in 
much the same way as later observed in humans after liver 
replacement. 53 Finally, GVHD was defined after trans-
plantation of the intestine alone by Monchik and Rus-
sell, 54 who used the parent to defenseless offspring first fil-
ial generation (F1) hybrid model. However, these last 
studies greatly overestimated the GVHD threat after in-
testinal and multi visceral organ transplantation for rea-
sons explained in Chapter 27. 
The multi visceral operation is not often indicated clini-
cally; aside from spawning many variations,4S however, it 
was itself the procedure with which the first long survival 
(>6 months) of a functioning human intestinal graft was 
accomplished. 55 
Pancreas Transplantation. Transplantation of the pan-
creas alone will not be considered in these historical notes 
because this procedure is performed only for endocrine 
objectives. However, the effect of pancreatic insulin secre-
tion on the liver is a vital concern with all liver engraft-
ments and other splanchnic transplantation procedures 
(see next section). Even the transplantation of the whole 
pancreas alone implies the concomitant engraftment of a 
segment of duodenum that receives exocrine pancreatic 
secretions and shares its blood supply with the pancreas in 
humans and animals (see Fig 1 - I b). Thus, it was not sur-
prising that pancreaticoduodenal grafts were used in the 
first reported acute experiments on pancreas transplanta-
tion. 56,57 When immunosuppression became available, 
essentially the same composite graft was used in dogs58 
and, eventually, in humans. 59 
ECK'S FISTULA AND HEPATOTROPHIC PHYSIOLOGY 
An erroneous concept about liver physiology was respon-
sible for Weich's belief that rejection was the sole explana-
tion for the rapid destruction of his auxiliary canine liver 
grafts.2, 4 The dogma had evolved from nearly 80 years of 
research with the experimental procedure of Eck's fistula 
(portacaval shunt) in dogs. In this procedure, blood re-
turning from the pancreas, intestines, and other splanch-
nic viscera via the portal vein was diverted around the 
liver. The liver shrinkage that occurred in dogs (and in 
rats, baboons, and humans)16. 60 and the consequent wast-
ing, hair loss, and brain damage were generally ascribed, 
until the mid-1960s, to the diminution of total hepatic 
blood flow rather than to the loss of exposure of the liver to 
any specific portal blood constituents.61 -64 This explana-
tion was called the flow hypothesis of portal physiology. 
Because Welch accepted this dogma and provided a high-
volume systemic venous flow for his auxiliary grafts, his 
belief that rejection was the sole reason for the rapid de-
struction of the auxiliary canine liver grafts was rational 
within the incorrect frame of reference of the time. 
Although he was wrong, Welch unwittingly created an 
experimental model of great power. The principle of the 
model was the coexistence in the same animal of two livers 
with similar conditions except for the different content of 
the blood delivered to the respective portal veins. When 
we repeated Welch's experiments in 1963 under immuno-
suppression, auxiliary livers protected from rejection by 
azathioprine but deprived of splanchnic venous inflow 
shrank within a few days to a fraction of their original 
size.6S This acute atrophy (Fig 1-7) was not seen in nor-
mally vascularized orthotopic livers,6' and it could be pre-
vented in auxiliary livers if they were nourished with 
normal portal blood. Under these circumstances, the 
shrinkage afIlicted the native liver, which had been de-
prived of its portal supply. 66 
Nontransplant models were soon developed in which 
the animal's own liver was divided into two fragments, 
each of which was vascularized with portal venous inflow 
from different organs or from different regions of the 
body67. 68 (Figs 1-8 and 1-9). It was apparent that the 
healthy and hypertrophic liver fragment with first access 
to the portal blood (see Fig 1 - 8), particularly that return-
ing from the upper abdominal viscera (see Fig 1-9), re-
moved hepatotrophic substances so completely tha.t little 
was left for the competing fragment, which shriveled up 
(Fig 1 - 10), Through the use of these double liver fragment 
models68- 71 and through organ extirpation experi-
ments,72, 73 insulin was shown to be the most important, 
but not the only, liver-supporting portal substance. Fi-
nally, it was shown that when infused continuously into 
the tied-off portal vein after portacaval shunt (Fig 1 - 11), 
insulin caused hyperplasia of the shrunken hepatocytes 
and prevented most of the atrophy and other adverse con-
sequences to the liver caused by the Eck fistula. 74 
As other liver growth factors became available, they 
were screened and evaluated for potency with the Eck fis-
tula model shown in Figure 1 - 11.75. 76 Active test sub-
stances that mimic the insulin effect include the im-
munosuppressive agents cyclosporine77 and FK506,78 
insulin-like growth factor, transforming growth factor-a, 
and hepatocyte growth factor. 76 By virtue of these develop-
ments, hepatotrophic physiology became a consistent col-
lateral theme of all research on the transplantation of the 
liver and other splanchnic organs and the common 
ground shared by liver transplantation, clinical portal 
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Figure 1-7 An auxiliary homograft (right) and the recipient dog's own liver (left) 45 days after 
transplantation. Note the well-preserved but dimensionally reduced general structure of the allograft. At 
the time of transplantation. both the host organ and the transplant were about the same size. (From 
Starzl TE. Marchioro Tl. Rowlands DT Jr. et aI. Immunosuppression after experimental and clinical 
homotransplantation of the liver. Ann Surg 160:411-439. 1964.) 
Figure 1-8 The operation of 
partial (split) transposition in dogs. 
Note that one of the main portal 
veins (left in A. right in B) retains 
the natural splanchnic flow and 
that the other one receives the 
total input of the suprarenal 
inferior vena cava. R.V. = renal 
vein. (A and B from Marchioro TL, 
Porter KA. Brown BI. et al. The 
effect of partial portacaval 
transposition on the canine liver. 
Surgery 61:723-732.1967.) 
lv.C. -rt. portal v. 
anastomoS1S 
oKvK~r (. 
I '" r" Ry. 
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PANCREATECTOMY 
Splanchnic division 
Figure 1-9 Splanchnic division experiments. In these dogs. the right liver lobes received venous 
return from the pancreaticogastroduodenosplenic region. and the left liver lobes received venous blood 
from the intestines. A. Nondiabetic dogs. B. Alloxan-induced diabetic dogs. C. Dogs with total 
pancreatectomy. (A to C from Starzi TE. Porter KA. Kashiwagi N. et al. The effect of diabetes mellitus 
on portal blood hepatotrophic factors in dogs. Surg Gynecol Obstet 140:549-562,1975. By 
permission of Surgery. Gynecology and Obstetrics.) 
~@ 
LEFT 
Figure 1-10 Hepatocyte shadows traced during histopathological 
examination of liver biopsy specimens from the experiments shown in 
Fig 1-9A. These traCings were later cut out on standard paper and 
weighed as an index of hepatocyte size. The right lobes. with the large 
hepatiC cells. received venous blood from the pancreas. stomach. 
duodenum. and spleen. The relatively shrunken left lobes. with the 
small hepatocytes. received intestinal blood. (From Starzl TE. 
Francavilla A. Halgrimson CG. et aI. The origin. hormonal nature. and 
action of hepatotrophic substances in portal venous blood. Surg 
Gynecol Obstet 137: 179-199. 1973. By permission of Surgery. 
Gynecology and Obstetrics.) 
shunt operations (all are variations of Eck's fistula), and 
the regeneration that follows hepatic resection. 16. 79 
IMMUNOSUPPRESSION 
After the demonstration by Medawar in 1944 that rejec-
tion is an immunological event,80, 81 the deliberate weak-
ening of the immune system was shown to ameliorate the 
rejection of skin grafts in rodents and renal grafts in dogs. 
This weakening was first accomplished with total body ir-
radiation,82 corticosteroid therapY,83.84 and much later, 
the thiopurine compounds 6-mercaptopurine and 
azathioprine.8s - 89 In these animal trials, however, com-
plete control of rejection with a single modality was rarely 
achieved without lethal side effects. The same pessimistic 
conclusion was made from the early clinical trials of renal 
transplantation90- 91 using total body irradiation, 6-mer-
captopurine, or azathioprine. 
This discouraging picture changed dramatically during 
1962 and 1963 in Colorado, when the synergism of aza-
thioprine and prednisone was discovered from animal in-
Figure 1-11 Experiments in 
which postoperative infusions of 
hormones are made into the left 
portal vein after performance of 
Eck's fistula. (From Starzl TE, 
Watanabe K, Porter KA, Putnam 
CWo Effects of insulin, glucagon, 
and insulin/glucagon infusions on 
liver morphology and call division 
after complete portacaval shunt in 
dogs. Lancet 1 :821-825, © by 
The Lancet Ltd, 1976.) 
Portacaval 
shunt 
vestigations.98 When these two drugs were used together in 
human kidney transplant recipients,99, 100 the results pre-
cipitated a revolution in clinical transplantation. Rejec-
tion could usually be reversed with prednisone, and then 
the amount of drugs required often lessened with 
time.99- 102 
The reversibility of rejection and an apparent but unex-
plained change in host-graft relationship were eventually 
verified with all other transplanted organs, beginning with 
the liver. 52. 103 Although immunosuppression has im-
proved, the central therapeutic strategy for whole organ 
transplantation that had emerged by 196399. 100 has 
changed very little in over 30 years. The dogma calls for 
daily treatment with one or two baseline drugs, and further 
immunomodulation with the highly dose-maneuverable 
adrenocortical steroids to whatever level is required to 
maintain stable graft function (Table 1 - 2). Every organ 
recipient goes through a trial and potential error experi-
ence as drug dosages are lowered to achieve maintenance 
levels. 
TABLE 1-2 Central therapeutic dogma of immunosuppression 
Strategy 
I. Baseline therapy with one or two drugs 
2. Secondary adjustments with steroids or antilymphoid agents 
3. Case to case trial (and potential error) of weaning 
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The principal regimens used clinically within this for-
mat for the ensuing 30 years are summarized in Table 1-
3.100- 114 Aside from the simplicity and the consequent ease 
with which the therapeutic formula could be taught, it 
proved applicable to each new drug regimen or immune-
modulating technique used clinically for the next 30 years 
and to each new organ, of which the liver was the first after 
the kidney and the intestine is the most recent. 
CLINICAL TRIALS OF LIVER TRANSPLANTATION 
Phase I: The Failed First Cases 
Once the effectiveness of the azathioprine-prednisone 
cocktail for kidney grafting had been established, a deci-
sion was taken atthe University of Colorado to move on to 
the liver.lIS. 116 The first recipient was a 3-year-old boy 
with biliary atresia who had had mUltiple previous opera-
tions. The transplantation could not be completed be-
cause of a fatal hemorrhage from venous collaterals and an 
Baseline Agents 
1. Azathioprine 
2. Cyclophosphamide 
3. Cyclosporine 
4. FK506 
Sites of Inhibition 
DNA synthesis 
DNA synthesis 
Interleukin-2 production 
Interleukin-2 production 
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TABLE 1-3 Principal immunosuppressive drug regimens and adjuncts used clinically· 
Year Used for 
Described Gastrointestinal 
Agents and Reported Place Deficiencies Organs 
Total body irradiation 196090 Boston Ineffective, dangerous no 
Azathioprine 196291 Boston Ineffective, dangerous no 
Azathioprine plus 196399 Denver Suboptimal yes, liver 
steroids 
Thoracic duct drainage 1963105 Stockholm Nuisance: requires yes,t liver 
as adjunct 20-30 days 
pretreatment 
Thymectomy as adjunct 1963106 Denver Unproven value yes, rarely in 1963 
Splenectomy as acljunct 1963106 Denver No longer necessary yes, once commonly 
for liver 
Antilymphocyte 1967107 Denver Suboptimal yes 
globulin as adjunct 
Cyclophosphamide 1971 108 Denver No advantage except yes,t liver 
substitute for for patients with 
azathioprine azathioprine toxicity 
Total lymphoid 1979109 Palo Alto, Minneapolis I>.ingerous,exterunve yes,§ for liver 
irradiation 1982110 preparation, not 
quickly reversible 
Cyclosporine 1978-1979111 Cambridge Suboptimal yes 
Cyclosporine plus 1980112 Denver Nephrotoxicity; yes 
steroids rejection not always 
controlled 
FK.506 plus steroids 1989114 Pittsburgh Nephrotoxicity; yes 
rejection not always 
controlled 
"Before 1966, these were developed with kidney transplantation and applied for livers; from 1966 on, the liver increasingly became the dominant test organ. 
tIt was not realized until much later that pretreatment for 3 to 4 weeks before transplantation was a necessary condition for effective use of thoracic duct drainage.lIl 
:j:These trials were summarized many years later with at least 10 years of follow-up for surviving patients.l9 
§By Professor J.A. Myburgh of Johannesburg. 
uncontrollable coagulopathy (prothrombin time infinity, 
platelet count <1O,OOO/mm3 ). Even for a team that had 
been fully prepared for technical vicissitudes by hundreds 
of animal operations, the exsanguination of this child was 
a terrible shock. 
Two more liver transplantations were carried out in the 
next 4 months. In both, the procedures seemed satisfac-
tory, but the recipients died after 22 and 7th days, respec-
tively. m, 116 The strategy of coagulation control (fresh 
blood or blood products, and E-aminocaproic acid for fi-
brinolysis) introduced after the death of the first patient 
had a delayed backfire in the next recipients in whom it 
was used. During the time when the livers were sewn in, 
the plastic external bypasses were used to reroute venous 
blood around the area of the liver in the same way as had 
been worked out in dogs. In the humans who were given 
coagulation-promoting therapy, clots formed in the by-
pass tubing and passed to the lungs. There they caused ab-
scesses and other lung damage that contributed to or 
caused delayed death in the first four patients who sur-
vived the intraoperative period.65, 115 A pall settled over 
the liver program, and a self-imposed moratorium fol-
lowed that lasted more than 3 vears. Bv this time, isolated 
attempts made in Boston1l7 and paris1l8 had also been 
unsuccessful. 
When these first seven liver transplantations failed in 
three different centers (Table 1-4), pessimism prevailed 
worldwide. The operation seemed too difficult to allow 
practical application. In addition, the methods of preser-
vation were assumed to be inadequate for an organ so 
seemingly sensitive to ischemic damage. Researchers 
began to ask whether the available immunosuppression 
was too primitive to permit success. This possibility was 
reinforced by the fact that long-term survival after liverre-
placement had not yet been achieved in experimental 
animals. 
Phase 2: Feasible but Impractical Therapy 
By the summer of 1967, these deficiencies had been atleast 
partially rectified by 3 more years of laboratory effort. 
Many long-term canine survivors had been obtained,s2 
and some dogs had passed the 3-year postoperative mark 
(Fig 1-12). Better immunosuppression with the so-called 
triple drug therapy was available since the development 
and first clinical trials of antilymphocyte globulin, which 
was prepared from sensitized horses107 and used to supple-
ment azathioprine and prednisone. Finally, techniques 
of organ preservation for as long as a day had been 
developed.119, 120 
..... -.>-I' •.•. ~-
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TABLE 1-4 The first seven attempts of clinical orthotopic liver transplantation 
Location Age Survival Main Cause 
Number (Reference) (Years) Disease (Days) of Death 
Denver l15 3 Extrahepatic biliary atresia 0 Hemorrhage 
2 Denver" 5 48 Hepatocellular cancer, cirrhosis 22 Pulmonary emboli, sepsis 
3 Denverll5 68 Duct cell carcinoma 71/2 Sepsis, pulmonary emboli, 
gastrointestinal bleeding 
4 Denver 68 52 Hepatocellular cancer, cirrhosis 61/2 Pulmonary emboli, hepatic failure, 
pulmonary edema 
5 Bostonl1 7 58 Metastatic colon carcinoma 11 Pneumonitis, liver abscesses, hepatic 
failure 
6 Denver6' 29 Hepatocellular cancer, cirrhosis 23 Sepsis, bile peritonitis, hepatic failure 
7 ParisI 18 75 Metastatic colon carcinoma 0 Hemorrhage 
On July 23, 1967, a Ph-year-old child with a huge hepa-
toma was restored almost immediately from a moribund 
state to seemingly good health after liver replacement. 
More cases followed. Most of the attempts made in 1967 
and 1968 were initially successful, but all of the patients 
eventually died; in addition, the first long-term survivor 
succumbed to recurrent cancer after 400 days. The maxi-
mum survival of the other six long-surviving liver recipi-
ents treated between July 1967 and March 1968 was 21h 
years.28• 29. 121 For the next 12 years, the I-year mortality 
rate after liver transplantation never fell below 50% in 
cases that were accrued at the University of Colorado at 
the rate of about one per month. The losses were concen-
Figure 1-12 Photograph (1968) of a dog whose orthotopic liver 
transplantation had been carried out in the spring of 1964. The animal 
died of old age after 11 % postoperative years. 
trated in the first postoperative months; after this initial 
period, the life survival curve flattened, leaving a residual 
group of stable and remarkably healthy survivors. Thirty 
(18%) of the first 170 patients in the consecutive series that 
started March 1, 1963 and ended in December 1979 lived 
more than ten years; 23 remained alive after 13 - 23 years. 
All were treated with azathioprine (or the anti-cancer 
agent, cyclophosphamide), prednisone, and polyclonal 
antilymphocyte globulin.29 
In the meantime, Roy CaIne of Cambridge University 
in England began clinical trials of liver transplantation on 
May 23, 1967. As had been our experience earlier, his first 
patient exsanguinated. l22 A few months later, Caine 
formed a collaboration that endured for more than 2 de-
cades with the hepatologist Roger Williams at King's Col-
lege Hospital in London. The extended survival of pa-
tients in both the Colorado and Cambridge-London series 
was a testimonial for liver transplantation. It was asked in-
creasingly on both sides of the Atlantic, however, ifsuch a 
small dividend could justify the prodigious effort that had 
brought liver transplantation this far. 123 
Other teams organized in Hanover (RudolfPichlmayr, 
1972) and Paris (Henri Bismuth, 1974) also reported the 
nearly miraculous benefits of liver transplantation when 
this treatment was successful, but always with the notation 
that the mortality rate was too high to allow its practical 
use. Liver transplantation remained a feasible but imprac-
tical operation. 
Phase 3: The Cyclosporine and FK506 Era 
The frustration ended when cyclosporine became avail-
able for clinical use in 1979111 and was combined with 
prednisone or lymphoid depletion in the first of the cyclo-
sporine-based cocktails. 112 Of our first 12 Ii ver recipients 
treated with cyclosporine and prednisone in the first 8 
months of 1980, 11 lived for more than a year,124 and 7 
were still alive over 12 years later. As the news was con-
firmed that a I-year patient survival rate of at least 70% 
was readily achievable, new liver programs proliferated 
worldwide. 
When FK506 was substituted for cyclosporine in 
1989,1l4 the I-year patient and liver graft survival rate rose 
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again in the Pittsburgh experience,12S an improvement 
similar to that in a multicenter European trial. By this 
time, liver transplantation had become the accepted court 
of last appeal for almost all non-neoplastic liver disease 
and even for selected patients with otherwise nonresect-
able hepatic malignancies. The principal limitation of the 
technology quickly became the small supply of organs to 
meet the burgeoning need. 
Although the ascension of liver transplantation was 
dominated by improvements in immunosuppression, 
there were other significant developments also, including 
modifications in the details of the operation itself. The in-
cidence of biliary duct complications (obstruction, fistula, 
and cholangitis), which had been more than 30%,126 was 
reduced by the use of choledochocholedochostomy with a 
T-tube stent or, if this was not feasible, by choledochoje-
junostomy to a Roux limb.29 Management of coagulopa-
thies was facilitated by the use of the thromboelastogram 
to follow the minute-ta-minute clotting changes in the 
operating room. liS, 127 The systematic use of venovenous 
bypasses without anticoagulation also greatly diminished 
the occurrence of hemorrhages of nightmare proportions 
common at one time. 
ORGAN PROCUREMENT: HYPOTHERMIA AND 
CORE COOLING 
Although few in number, steps in the development of liver 
graft procurement and preservation established principles 
that could be applied to other whole organs. The first was 
core cooling by infusion of chilled., lactated Ringer's solu-
tion into the portal vein,9 a laboratory technique soon 
modified for use in clinical kidney transplantationl28 and 
subsequently for other organs. 
Pump 
Today, core cooling is the initial stage in the preserva-
tion of all whole organs. However, in contrast to the origi-
nal method of skeletonization and removal of the individ-
ual grafts before infusion of chilled fluids, core cooling is 
performed by variations of the in situ technique originally 
developed before the acceptance of brain death condi-
tions. This technique involved continuous hypothermic 
perfusion of cadaveric kidney and liver donorsl29, 130 (Fig 
1-13). Ackerman and Snell131 and Merkel and col-
leagues132 simplified the in situ cooling of cadaveric kid-
neys with cold electrolyte solutions infused into the distal 
aorta, without continuous perfusion. 
Eventually, in situ cold infusion techniques were per-
fected that allowed removal of all thoracic and abdominal 
organs, including the liver, without jeopardizing any of the 
individual organsl33 (Fig 1-14). Modifications of this pro-
cedure were made for unstable donors and even for donors 
whose hearts had ceased to beat. l34 By 1987, multiple 
organ procurement techniques were interchangeable not 
only from city to city but from country to country and had 
become standardized in all parts ofthe world. Today, after 
the chilled organs have been removed, subsequent preser-
vation may be by simple refrigeration or by sophisticated 
methods of continuous perfusion. 
INDICATIONS FOR LIVER TRANSPLANTATION 
Benign Disease Categories 
By 1989, the list of benign diseases treatable by transplan-
tation had become so long (nearly 100) that it was being 
divided into broad categories (Table 1 - 5) such as choles-
tatic disorders and those involving the parenchyma.13S, 135. 
Because products of hepatic synthesis permanently retain 
Figure 1 -13 The first technique 
of in situ cooling by extracorporeal 
hypothermic perfusion. The 
catheters were inserted via the 
femoral vessels into the aorta and 
vena cava as soon as possible 
after death. Temperature control 
was provided with a heat 
exchanger. Crossclamping of the 
thoracic aorta limited perfusion to 
the lower part of the body. This 
method of cadaveric organ 
procurement was used from 1962 
to 1969. before the acceptance of 
brain death. The preliminary 
stages of this approach provided 
the basis for subsequent in situ 
infusion techniques. (From Starzl 
TE. Experience in Renal 
Transplantation. Philadelphia, WB 
Saunders, 1964, p 56.) 
Figure 1 -14 Principle of in situ cooling used for multiple organ 
procurement. With limited preliminary dissection of the aorta and great 
splanchnic veins (in this case the splenic vein), cold infusates can be 
used to chill organs in situ. In this case, the kidneys and liver were to 
be removed. Note the aortic crossclamp above the celiac axis. 
(Redrawn from Starzl TE, Hakala TR, Shaw BW Jr, et aI. A flexible 
procedure for multiple cadaveric organ procurement. Surg Gynecol 
Obstet 158:223-230, 1984. By permission of Surgery, Gynecology 
and Obstetrics.) 
the original metabolic specificity of the donor after trans-
plantation,135, 136 the correction of inborn errors by liver 
transplantation can be expected to endure for the life of 
the graft. Sixteen liver-based or liver-influenced inborn 
errors of metabolism have been compiled under the in-
born error category of indications (Table 1 -6). 
Trimming the Contraindication List 
A number of diseases that precluded transplantation 5 -1 0 
years ago, such as alcoholic cirrhosis, are no longer abso-
lute contraindications. Scarring from multiple upper ab-
dominal operations and prior portosystemic shunts have 
been eliminated as serious adverse factors in major 
centers. Extensive thrombosis of the portal and superior 
mesenteric veins, which previously made liver transplan-
tation difficult or impossible, has been almost eliminated 
as a deterrent to transplantation by the use of vein 
grafts137-141 (Fig 1-15). The systematic use of arterial and 
venous grafts was introduced at the University of Colo-
rado in the 1970s.137 Harvesting these life-saving conduits 
was made an integral component of the cadaveric organ 
procurement procedure thereafter. 133 A particularly use-
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TABLE 1-5 Generic listing of liver diseases treatable by liver 
transplantation 
Disease 
Parenchymal 
Postnecrotic cirrhosis 
Alcoholic cirrhosis 
Acute liver failure 
Budd-Chiari syndrome 
Congenital hepatic fibrosis 
Cystic fibrosis 
Neonatal hepatitis 
Hepatic trauma 
Cholestatic 
Biliary atresia 
Primary biliary cirrhosis 
Sclerosing cholangitis 
Secondary biliary cirrhosis 
Familial cholestasis 
Inborn Errors of Metabolism 
Tumors 
Benign 
Primary malignant 
Metastatic 
ful technique has been the antepancreatic venous jump 
graft first described by Sheil et al139 of Sydney (Fig 1-16). 
Similarly, inflexible age proscriptions at either the 
upper or lower range were dropped by the mid-1980s. The 
shortage of appropriate-sized donors forvery smaIl pediat-
ric recipients was greatly ameliorated by the use of liver 
fragments. The first known reduced liver graft operation 
was performed in Denver in 1975,142 but it was not re-
ported until long after the landmark descriptions of this 
technique by Henri Bismuth and Didier Houssin of 
Paris143 and by the team of Rudolf Pichlmayr and Chris-
toph Broelsch et al of Hanover. l44 In 1989, Lynch and 
Strong successfully transplanted a portion of the left lobe 
from a living related donor,145 a procedure further refined 
and popularized by Broelsch during a stint at the Univer-
sity of Chicago. 146 These liver reduction procedures were 
facilitated by the use of the piggyback principle by which 
the recipient retrohepatic vena cava is kept intact and the 
suprahepatic venous outflow of the graft is anastomosed to 
cuffs of the hepatic veins (Fig 1-17). The piggyback modi-
fication was first described by Calne122 for the transplanta-
tion of pediatric livers into adults; it was used sporadically 
for many years and ultimately popularized by Tzakis et 
al. l47 
Neoplastic Diseases 
The use of conventional liver transplantation to treat 
otherwise nonresectable primary or metastatic hepatic 
cancers has resulted in a very high rate of recurrence. I3S 
Nevertheless, the use of liver transplantation to treat 
cancer is still being investigated by many transplantation 
teams, almost invariably in combination with adjuvant 
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TABLE 1 - 6 Inborn errors of metabolism treated with liver transplantation.· 
Disease 
ai-Antitrypsin deficiency 
Wilson's disease 
Tyrosinemia 
Type I glycogen storage disease 
Type IV glycogen storage disease 
Cystic fibrosis 
Niemann-Pick disease 
Sea-blue histiocyte syndrome 
Erythropoietic proto porphyria 
Crigler-Najjar syndrome 
Type I hyperoxaluria 
Urea cycle enzyme deficiency (three 
types) 
C protein deficiency 
Familial hypercholesterolemia 
Hemophilia A 
Hemophilia B 
Explanation of Disease 
Structural abnormality of the protease 
inhibitor synthesized in the liver 
Abnormal biliary copper excretion, 
decreased copper binding to cerulo-
plasmin, and copper accumu-
lation in tissues; autosomal reces-
sive gene mapped to chromosome 13 
Fumaroylacetoacetate hydrolase 
deficiency 
Glucose-6-phosphatase deficiency 
Amylo-I : 4, I : 6-transglucosidase 
(branching enzyme) defect 
Unknown; pancellular disease, liver 
often affected 
Sphingomyelinase deficiency, 
sphingomyelin storage 
Unknown, neuroviscerallipochrome 
storage 
Hepatic ferrochelatase deficiency, 
?overproductive of protoporphyrin by 
erythropoietic tissues 
Glucuronyl transferase deficiency 
Peroxisomal alanine: glyoxyJate 
aminotransferase deficiency 
Ornithine carbamoyltransferase 
deficiency 
Defective C protein synthesis 
Low-density lipoprotein receptor 
deficiency, low-density lipoprotein 
overproduction 
Factor VIII deficiency 
Factor IX deficiency 
Longest 
Survival 
13 yr 
J61hyr 
71h yr 
7yr 
41h yr 
41fz yr 
2 yr (died) 
7yr 
Ilh yr 
4yr 
Smo 
Smo 
2V4 yr 
6yr 
4yr 
6mo 
Associated Liver 
Disease 
Cirrhosis 
Cirrhosis 
Cirrhosis, hepatoma 
Glycogen storage, fibrosis, tumors 
Cirrhosis 
Cirrhosis 
None 
Cirrhosis 
Cirrhosis 
None 
None 
None 
None 
None 
Cirrhosis, a complication of blood 
component therapy 
Cirrhosis, a complication of blood 
component therapy 
From Starzl TE, Demetris AJ, Van Thiel DH. Medical progress: Liver transplantation. Part I, N Eng! J Med 321:1014-1022; Part II, 321:1092-1099. Reprinted by 
permission of The New England Journal of Medicine, 1989. Copyright 1989, Massachusetts Medical Society. 
·Most of the patients were in the University of Colorado-University ofPittsburgb series. Follow-up to January 1989. 
chemotherapy or other experimental treatment protocols. 
Certain kinds of neoplasms have a better prognosis than 
others (Chapter 12). A radical extension of this attempt to 
increase the perimeter of resectability is the removal of 
upper abdominal organs en bloc (liver, pancreas, spleen, 
stomach, duodenum, proximal jejunum, and right colon) 
(Fig 1-18) to treat extensive sarcomas and carcinoid 
tumors that are still regionally confined. 148 The excised 
organs are replaced with hepatopancreaticoduodenal 
grafts (Fig 1 - 19) or, in some cases, by the liver alone. 
CLINICAL TRIALS OF INTESTINAL 
TRANSPLANTATION WITH THE LIVER IN 
COMPOSITE VISCERAL GRAFTS OR ALONE 
Composite Grafts 
Function of a cadaveric intestine for more than 6 months 
was not accomplished until 1987. In November of that 
year, a recipient of a multi visceral graft who was treated 
with cyclosporine, prednisone, and the antilymphoid 
agent OKT3 survived for 192 days before dying of a B cell 
Arterial graft from 
infrarenal aorta 
Figure 1-15 By 1979. all of the demonstrated grafts had been used 
clinically. The use of vascular grafts has been life saving; liver 
transplantation should never be attempted without an emergency 
assortment of these grafts. (Redrawn from Starzl TE. Halgrimson eG. 
Koep LJ. et aI. Vascular homografts from cadaveric organ donors. 
Surg Gynecol Obstet 149:76-77.1979. By permission of Surgery. 
Gynecology and Obstetrics.) 
Figure 1-17 Transplantation of a liver 
piggybacked onto an inferior vena cava. which is 
preserved through its length. Note that the 
suprahepatic vena cava of the homograft is 
anastomosed to the anterior wall of the recipient 
vena cava. The retrohepatic vena cava of the 
homograft is sutured or ligated, leaving a blind sac 
into which empty numerous hepatic veins. (From 
Tzakis A, Todo S, Starzl TE. Orthotopic liver 
transplantation with preservation of the inferior 
vena cava. Ann Surg 210:649-652,1989.) 
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Figure 1 -16 An antepancreatic route for a vascular graft placed 
onto the infrarenal abdominal aorta, as originally described by Sheil.139 
The graft is brought to the right or left of the middle colic vessels. 
anterior to the pancreas and beneath the pylorus. (From Tzakis A, 
Todo S. Steiber A. Starzl TE. Venous jump grafts for liver 
transplantation in patients with portal vein thrombosis. Transplantation 
48:530-531. 1989.) 
Portal v (r) 
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Figure 1-18 Delineation in embryonal life (left) of that region of the gastrointestinal tract (darkly 
shaded) that was resected in an organ cluster operation (E = esophagus; LB = lung bud; L = liver; 
P = pancreas). The adult organs (right) deriving from the shaded primitive analog are shown. (From 
Starzl TE, Todo S, Tzakis A. Abdominal organ cluster transplantation for the treatment of upper 
abdominal malignancies. Ann Surg 210:374-386, 1989.) 
lymphoma. ss Several subsequent recipients of the full 
multivisceral graft (see Fig 1-6, left) are alive after as long 
as 17 months under treatment with FK506. 149 
A variant procedure in which only the liver and small 
bowel are retained (see Fig I-Ie and Fig 1-6, right) was 
first described and used successfully by Grant and co-
workers 1 so of London, Ontario (Canada). This operation 
has been particularly useful in patients with the short gut 
syndrome who developed liver failure after prolonged hy-
peralimentation.43 With. the use ofFK506, 13 (76.5%) of 
17 patients treated by Starzl and colleaguesl49 in the Pitts-
burgh series of liver-intestine grafts were alive after 5 - 31 
months, and all but one had been liberated from total pa-
renteral nutrition. 
Intestinal Transplantation Alone 
As recently as late 1991, some workers in the field believed 
that the protection to the intestine afforded by the con-
comitant transplantation of the liver from the same donor 
(see earlier) was sufficiently great to justify combined liver 
and intestinal transplantation even when only a techni-
cally simpler intestinal transplant was needed. Enthusi-
asm for this draconian strategy began to fade with the suc-
cessful transplantation in March 1989 of a cadaveric small 
intestine by Goulet and colleagueg42 of Paris, and of an 
ileal segment from a living related donor by Deitz et al of 
Kiel, Germany.151 
These were isolated straws in the wind. In Pittsburgh, 
the routine survival of cadaveric intestinal recipients then 
became possible under immunosuppression with FK506; 
the results have been better with isolated intestinal trans-
plantation than with either the multivisceral operation or 
its liver-intestine variant.43, 149, 152 Eight of nine such recip-
ients are alive, several after 1 - 2 years, and all but one are 
free from total parenteral nutrition. The expected release 
of FK506 for general use in the near future is certain to 
stimulate rapid further development of the intestinal 
transplantation field. 
Metabolic Interactions 
Normally, the venous effluent from all nonhepatic 
splanchnic organs contributes to the portal blood supply, 
assuring the liver first-pass exposure to the intestinal nu-
trients and to the so-called portal hepatotrophic sub-
stances of which insulin is the most important. This factor, 
which is operational for native livers and transplanted 
ones, should be considered in any intra-abdominal vis-
ceral transplantation, whether it be of the liver or intestine 
alone or one of the multivisceral procedures that alter the 
portal circulation. 
For example, when partial multivisceral grafts such as 
that of the liver and intestine are used in recipients whose 
pancreas and other upper abdominal organs are retained, 
it is preterable to direct the venous eflluent from the resid-
~KD .. -
Figure 1 -19 Completed reconstruction in the recipient after a 
cluster resection (upper abdominal exenteration). (From Starzl TE. 
Todo S, Tzakis A. Abdominal organ cluster transplantation for the 
treatment of upper abdominal malignancies. Ann Surg 210:374-386, 
1989.) 
ua1 host organs into the portal circulation of the new liver 
(see Fig 5B). If this is not done, injury to the liver that is 
typical of, although less severe than, that caused by Eck's 
fistula can occur. Similarly, when the intestine is trans-
planted alone, the ideal route of graft venous return is 
through the native liver. However, the inability to drain 
intestinal return into the host liver for technical reasons 
has not caused severe hepatic complications in a small 
number of human recipients.43 
MECHANISM OF GRAFT ACCEPTANCE 
Throughout the modem history of transplantation, it was 
not known how grafts were able, with the aid ofimmuno-
suppression, to resist the onslaught of rejection and later 
merge half forgotten into the host. In 1992, the study of 
liver, kidney, and other organ recipients who had survived 
for as long as 3 decades provided unique insights into this 
process (Chapter 27). In all successful cases, donor leuko-
cytes (principally dendritic cells) could be demonstrated in 
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the skin lymph nodes, heart, and other tissues of the long-
surviving hosts. 
These chimeric cells that had emigrated from the grafts 
and then perpetuated themselves for many years were 
present in larger numbers at any given peripheral site in 
liver recipients than in patients carrying other trans-
planted organs, such as the kidney.1S3-IS6 The heavy en-
dowment of the liver with these potentially migratory cells 
is now thought to be the basis for hepatic tolerogenicity, 
which allows the liver to induce its own acceptance more 
readily than other organs can. In some experimental 
models, graft acceptance has occurred without immuno-
suppression. This mechanism of acceptance is postulated 
to be the basis by which donor livers shield concomitantly 
transplanted organs from rejection and even resist the at-
tack of preformed antibodies. These discoveries have ne-
cessitated a paradigm shift in many aspects oftransplanta-
tion immunology, as discussed in Chapter 27. 
WHOLE ORGAN XENOTRANSPLANTATION 
When organs are transplanted from a significantly dispar-
ate species, the first immunologic hurdle is that of pre-
formed xenospecific antibodies that quickly devascularize 
the graft and exclude it from recipient circulation by dam-
aging its blood vessels. IS7 The liver is subject to this hu-
moral (hyperacute) rejection, but it was demonstrated 
more than 20 years ago to be unusually resistant to the in-
jury caused by antigraft antibodies. IS8 When the antibody 
barrier is surmounted, as has been possible with the adju-
vant use of antimetabolite drugs such as cyclophospha-
mide,ls9 the subsequent events of xenograft acceptance 
involve the same cell migration and consequent systemic 
chimerism as with allotransplantation. IS7 
Human liver xenotransplantation using chimpanzee 
donorsl60 was attempted three times between 1966 and 
1973 with deaths after 0, 9, and 14 daYS.161 The clinical 
evolution and histopathological findings were jndistin-
guishable from those after allotransplantation. Two addi-
tional hepatic xenotransplantations were attempted, in 
June 1992 and January 1993, with the phylogenetically 
more distant baboon donor. Survival was 70 and 26 
daYS.162, 163 Neither antibody nor cell-mediated rejection 
could be indicted as the cause of death of these patients; 
both of them had systemic chimerism in life and at au-
topsy. However, neither xenograft functioned optimally, 
and both developed findings of intrahepatic cholestasis 
within the first postoperative week. The dichotomy of his-
topathological findings and clinical course has raised sus-
picions that synthetic products of the baboon liver may 
have been incompatible with the human metabolic envi-
ronment. If so, the main importance of this experience 
may have been as a forerunner to xenotransplantation of 
metabolically less complex organs such as the kidney and 
heart. 
The author's present opinion, however, is that the inad-
equate graft function was related to the early injury of 
these organs by inflammatory mediators triggered by pre-
formed xenospecific antibodies (principally immunoglob-
ulin M) and complement activation. This pathogenesis is 
similar to that defined 25 years ago as the basis for hyper-
acute rejection of kidney allograftsl64. 16S and, more re-
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cently, the humoral rejection ofliver allografts. 166, 167 The 
use of a new generation of complement inhibitors168 may 
provide the missing piece in the treatment mosaic that will 
make liver xenotransplantation possible. 169 
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